Nektar Therapeutics [NKTR] stock is trading at $1.67, up 5.70%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The NKTR shares have gain 26.52% over the last week, with a monthly amount glided 96.47%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Previously, TD Cowen upgraded its rating to Outperform on November 09, 2023. On May 10, 2023, upgrade upgraded it’s rating to Hold and revised its price target to $1 on the stock. Jefferies downgraded its rating to a Underperform and decreased its price target to $1.50 on February 24, 2023. JP Morgan downgraded its rating to a Underweight. In a note dated April 18, 2022, Goldman downgraded an Sell rating on this stock but restated the target price of $3.
Nektar Therapeutics [NKTR] stock has fluctuated between $0.41 and $1.75 over the past year. Currently, Wall Street analysts expect the stock to reach $16.75 within the next 12 months. Nektar Therapeutics [NASDAQ: NKTR] shares were valued at $1.67 at the most recent close of the market. An investor can expect a potential return of 902.99% based on the average NKTR price forecast.
Analyzing the NKTR fundamentals
Nektar Therapeutics [NASDAQ:NKTR] reported sales of 90.12M for the trailing twelve months, which represents a growth of 8.45%. Gross Profit Margin for this corporation currently stands at 0.63% with Operating Profit Margin at -1.81%, Pretax Profit Margin comes in at -3.07%, and Net Profit Margin reading is -3.06%. To continue investigating profitability, this company’s Return on Assets is posted at -0.69, Equity is -1.52 and Total Capital is -0.47. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of1.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.5417 points at the first support level, and at 1.4133 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.7367, and for the 2nd resistance point, it is at 1.8033.
Ratios To Look Out For
For context, Nektar Therapeutics’s Current Ratio is 6.45. In addition, the Quick Ratio stands at 6.14 and the Cash Ratio stands at 0.39. Considering the valuation of this stock, the price to sales ratio is 3.40, the price to book ratio is 2.44.
Transactions by insiders
Recent insider trading involved ROBIN HOWARD W, President & CEO, that happened on Feb 20 ’24 when 20033.0 shares were sold. Chief R&D Officer, Zalevsky Jonathan completed a deal on Feb 20 ’24 to sell 9014.0 shares. Meanwhile, Chief Legal Officer Wilson Mark Andrew sold 7606.0 shares on Feb 20 ’24.
